Introduction {#s1}
============

Non Syndromic hereditary Hearing Loss (NSHL) is one of the most genetically heterogeneous disorders known. Indeed it can present an autosomal recessive, autosomal dominant, X-linked or mitochondrial pattern of inheritance; furthermore, mutations in the same gene may cause syndromic or non syndromic hearing loss, and recessive forms may be caused by a combination of two mutations in different genes from the same functional group [@pone.0012742-Schrijver1].

Due to this tremendous genetic heterogeneity, the identification of genes and gene defects that affect the process of hearing is challenging [@pone.0012742-Schrijver1]. At present 51 genes have been already identified to be responsible, if mutated, for this phenotype (see [Table 1](#pone-0012742-t001){ref-type="table"} for references); nevertheless not all these genes have been fully characterized. They usually are involved in the inner ear development or functionality, and their mutations generally cause hearing loss interfering in the process of the elaboration of sound.

10.1371/journal.pone.0012742.t001

###### NSHL disease genes.

![](pone.0012742.t001){#pone-0012742-t001-1}

  Gene Symbol         Locus Name        Chromosomal Location                                   References
  -------------- --------------------- ----------------------- --------------------------------------------------------------------------
  DIAPH1                 DFNA1               \[5q31.3c\]                                 [@pone.0012742-Lynch1]
  GJB3                   DFNA2               \[1p34.3f\]                                  [@pone.0012742-Xia1]
  KCNQ4                  DFNA2               \[1p34.2c\]                                [@pone.0012742-Kubisch1]
  GJB2               DFNA3/DFNB1A           \[13q12.11a\]                               [@pone.0012742-Kelsell1]
  GJB6               DFNA3/DFNB1B           \[13q12.11b\]                 [@pone.0012742-Grifa1], [@pone.0012742-delCastillo1]
  MYH14                  DFNA4              \[19q13.33c\]                               [@pone.0012742-Donaudy1]
  DFNA5                  DFNA5               \[7p15.3a\]                                [@pone.0012742-VanLaer1]
  WFS1               DFNA6/DFNA14            \[4p16.1f\]                   [@pone.0012742-Bespalova1], [@pone.0012742-Young1]
  TECTA           DFNA8/DFNA12/DFNB21       \[11q23.3h\]                               [@pone.0012742-Verhoeven1]
  COCH                   DFNA9               \[14q12e\]                                [@pone.0012742-Robertson1]
  EYA4                  DFNA10               \[6q23.2c\]                                 [@pone.0012742-Wayne1]
  MYO7A              DFNA11/DFNB2           \[11q13.5c\]                                  [@pone.0012742-Liu1]
  COL11A2            DFNA13/DFNB53          \[6p21.32a\]                                [@pone.0012742-McGuirt1]
  POU4F3                DFNA15                \[5q32d\]                                 [@pone.0012742-Vahava1]
  MYH9                  DFNA17              \[22q12.3d\]                                [@pone.0012742-Lalwani1]
  ACTG1              DFNA20/DFNA26          \[17q25.3f\]                     [@pone.0012742-Zhu1], [@pone.0012742-vanWijk1]
  MYO6               DFNA22/DFNB37           \[6q14.1a\]                              [@pone.0012742-Melchionda1]
  GRHL2                 DFNA28           \[8q22.3a-q22.3b\]                             [@pone.0012742-Peters1]
  TMC1            DFNA36/DFNB7/DFNB11       \[9q21.13a\]                                [@pone.0012742-Kurima1]
  CRYM                  DFNA40              \[16p12.2b\]                                  [@pone.0012742-Abe1]
  CCDC50                DFNA44                \[3q28d\]                              [@pone.0012742-ModamioHybjr1]
  MYO1A                 DFNA48              \[12q13.3a\]                                [@pone.0012742-Donaudy2]
  KCNJ10                DFNA49               \[1q23.2c\]                                 [@pone.0012742-Yang1]
  MIRN96                DFNA50               \[7q32.2a\]                                 [@pone.0012742-Menca1]
  MYO15A                 DFNB3          \[17p11.2g-7p11.2f\]                             [@pone.0012742-Wang2]
  SLC26A4                DFNB4               \[7q22.3c\]                                  [@pone.0012742-Li1]
  TMIE                   DFNB6              \[3p21.31a\]                                  [@pone.0012742-Naz1]
  TMPRSS3            DFNB8/DFNB10           \[21q22.3b\]                                 [@pone.0012742-Scott1]
  OTOF                   DFNB9               \[2p23.3b\]                               [@pone.0012742-Yasunaga1]
  CDH23                 DFNB12          \[10q22.1d-10q22.1e\]                            [@pone.0012742-Bork1]
  STRC                  DFNB16              \[15q15.3a\]                                 [@pone.0012742-Verpy2]
  USH1C                 DFNB18              \[11p15.1d\]                    [@pone.0012742-Ouyang1], [@pone.0012742-Ahmed1]
  OTOA                  DFNB22              \[16p12.2a\]                              [@pone.0012742-Zwaenepoel1]
  PCDH15                DFNB23          \[10q21.1b-10q21.1c\]                            [@pone.0012742-Ahmed2]
  RDX                   DFNB24              \[11q22.3d\]                                 [@pone.0012742-Khan1]
  TRIOBP                DFNB28              \[22q13.1a\]                  [@pone.0012742-Shahin1], [@pone.0012742-Riazuddin1]
  CLDN14                DFNB29              \[21q22.13a\]                               [@pone.0012742-Wilcox1]
  MYO3A                 DFNB30              \[10p12.1b\]                                 [@pone.0012742-Walsh1]
  WHRN(DFNB31)          DFNB31                \[9q32e\]                                  [@pone.0012742-Mburu1]
  ESRRB                 DFNB35              \[14q24.3c\]                    [@pone.0012742-Ansar1], [@pone.0012742-Collin2]
  ESPN                  DFNB36              \[1p36.31a\]                                  [@pone.0012742-Naz2]
  HGF                   DFNB39          \[7q21.11c-q21.11d\]                            [@pone.0012742-Schultz1]
  KIAA1199              DFNB48              \[15q25.1b\]                                  [@pone.0012742-Abe2]
  MARVELD2              DFNB49               \[5q13.2a\]                               [@pone.0012742-Riazuddin2]
  PJVK(DFNB59)          DFNB59               \[2q31.2b\]                              [@pone.0012742-Delmaghani1]
  SLC26A5               DFNB61               \[7q22.1g\]                                  [@pone.0012742-Liu2]
  LRTOMT                DFNB63               \[11q13.4\]                                 [@pone.0012742-Ahmed3]
  LHFPL5             DFNB66/DFNB67          \[6p21.31b\]        [@pone.0012742-Tlili1], [@pone.0012742-Shabbir1], [@pone.0012742-Kalay1]
  PRPS1                  DFN2                \[Xq22.3b\]                                  [@pone.0012742-Liu3]
  POU3F4                 DFN3                \[Xq21.1d\]                                 [@pone.0012742-DeKok1]
  ATP2B2                                     \[3p25.3b\]                  [@pone.0012742-Schultz2], [@pone.0012742-Ficarella1]

GeneIDs are from NCBI Entrez Gene database; gene symbols correspond to the official gene names as provided by HUGO Gene Nomenclature Committee (HGNC); locus names have been inferred from literature; chromosomal locations are derived from the file cyto_gene.md downloaded from the NCBI Entrez Gene ftp site and references are relative to the articles where the gene association to NSHL was identified.

About 50% of cases of NSHL are due to mutations of GJB2, a gene coding for a gap-junction protein called connexin 26, involved in the cell-cell communication process. Another important gene responsible for NSHL is GJB6, belonging to the same family of GJB2 and adjacent to it. The identification of these two genes highlighted the role of connexins, and therefore of the cochlear gap-junction ion channels, in the auditory function [@pone.0012742-Kelsell1], [@pone.0012742-Grifa1].

However the biology of hearing is extremely complex and many other different classes of genes are involved in NSHL. For instance, SLC26A4, associated with autosomal recessive NSHL [@pone.0012742-Li1] and Pendred syndrome, is a gene coding for pendrin, a chloride/iodide transporter; COCH, responsible for autosomal dominant non syndromic post-lingual with a progressive onset in adulthood [@pone.0012742-Robertson1], encodes for cochlin, a component of the extracellular matrix of the inner ear; POU3F4, responsible for an X-linked non syndromic progressive and profound sensorineural hearing loss [@pone.0012742-DeKok1], encodes for a transcription factor; while WFS1 associated with autosomal recessive Wolfram syndrome and autosomal dominant low frequency NSHL [@pone.0012742-Bespalova1], [@pone.0012742-Young1], is a gene coding for the glycoprotein wolframin.

Moreover, several linkage studies over the years have shown that many chromosomal regions are involved in NSHL. At present 121 loci are known to be involved in this phenotype [@pone.0012742-Hereditary1], and for many of them the genes causing NSHL have not been identified yet. Due to their often extremely large dimensions -- they can even contain several hundreds of genes -- it is not feasible to experimentally validate all the genes contained in each locus. In addition, some loci might contain more than one disease gene, as in the case of DFNA3 that harbors GJB2 and GJB6.

In this scenario, a bioinformatic approach to narrow down the list of possible candidate genes is an essential requirement in order to experimentally validate first those genes most likely associated with the disease.

Many strategies have been devised to address this issue, mostly sharing the common prioritization idea of ranking the candidate genes on the basis of their similarity with a set of training genes -- genes already associated to the phenotype -- relying on the main assumption that genes whose dysfunction contributes to a disease phenotype tend to be functionally related (see [@pone.0012742-Linghu1] and references within).

Quantifying the functional relatedness between two genes is not trivial; often existing information about gene function are exploited to infer functional relationships among genes. In this kind of approach an excellent means is provided by Gene Ontology (GO, The Gene Ontology Consortium, 2001) [@pone.0012742-Ashburner1], which is the golden standard ontology in the field of genes and gene products.

Indeed one of the advantages of having genes annotated with GO terms is the possibility to compare them not only from a qualitative point of view (e.g. by searching for common terms with which they are annotated), but also by defining an explicit semantic similarity measure which reflects the closeness in meaning between the terms with which they are annotated [@pone.0012742-Pesquita1], [@pone.0012742-Lord1]. This semantic similarity measure gives in turn a measure of the functional similarity of the annotated gene products, as extensively discussed in Pesquita et al [@pone.0012742-Pesquita1].

Briefly, when comparing two terms in an ontology, two main approaches are generally distinguished, the edge-based, which counts the edges in the graph path between two terms [@pone.0012742-Wu1]--[@pone.0012742-delPozo1], and the node-based, which looks at the properties of the terms, their ancestors and descendants [@pone.0012742-Resnik1]--[@pone.0012742-Lin1]. Most of the node-based similarity measures are functions of the information content (*IC*) of each term, and their most informative common ancestors [@pone.0012742-Lin1]. *IC* is the amount of information a term contains, meaning that a term contains less information if it occurs very often; in this context the similarity between two terms is quantified looking at the amount of information they share. Very often gene products are annotated with multiple GO terms, in this case maximum [@pone.0012742-Sevilla1], [@pone.0012742-Riensche1], average [@pone.0012742-Lord1], [@pone.0012742-delPozo1], [@pone.0012742-Wang1] or sum [@pone.0012742-Lei1] of the GO term similarities may be taken as the gene similarity.

Here we define a new Semantic Similarity Measure (*SSM*) between gene products by directly extending to sets of concepts (the gene annotations) the Lin\'s idea [@pone.0012742-Lin1] of quantifying the similarity between two concepts in an ontology. Our metric provides a measure of the functional similarity between two genes and its reliability is tested in this paper in the context of gene prioritization for NSHL. Indeed the overall aim of this paper is (i) to support researchers in search of new genes responsible for NSHL and (ii) provide indications about the main biological processes, molecular functions and cellular components to be explored to study NSHL, by defining a procedure to computationally prioritize candidate genes for their association with this phenotype. The availability of a good training gene set for NSHL -- 51 genes already associated with this phenotype (disease genes) -- allows to select new genes most likely responsible for this phenotype estimating their similarity with the disease gene set.

Finally we define a systematic and unbiased statistical assessment to validate the obtained results.

Results {#s2}
=======

The candidate genes prioritized for NSHL in this study were selected as described in the [Methods](#s4){ref-type="sec"} section. They were prioritized against all the genes already known to be responsible for NSHL (disease genes, see [Methods](#s4){ref-type="sec"} section for details on their selection), according to a score which is function of the Semantic Similarity Measure () estimated for each candidate-disease gene pair. All candidate genes were ranked by computing the for each candidate-disease gene pair; the final score used for prioritizing each candidate was obtained as the mean of the scores estimated for that candidate against all the disease genes and was defined Semantic Similarity Measure Average ().

Validation of the for NSHL gene prioritization {#s2a}
----------------------------------------------

Before being able to assert that the ranking produced by is worthy of attention and therefore evaluating it from a biological point of view, we wanted to evaluate two main aspects concerning our prioritization methodology. We first wanted to test whether the main hypothesis upon which this and most of the prioritization studies are based -- genes whose dysfunction contributes to a disease phenotype tend to be functionally related -- is quantifiable in terms of semantic similarity, especially in the particular case of NSHL, where the complexity of the hearing process and the complexity of the genetics of the disease both play an important role. Second aspect is whether our metric is able to catch this functional relatedness. To test these two aspects is equivalent to answer the following question: are the disease genes more functionally related than two generic human genes according to ? A positive answer would yield a positive result for both aspects at the same time, implying that the more a candidate gene obtains a high score respect to the disease gene set, the higher is its probability to cause NSHL when mutated. To address this issue, we estimated the pair-wise *SSM* distribution on the disease gene set, and compared it with the pair-wise *SSM* distribution estimated on the entire human gene set. In [Figure 1](#pone-0012742-g001){ref-type="fig"} a population pyramid shows the pair-wise *SSM* distribution across the disease genes and All-human-genes sets in two back-to-back histograms. It provides the graphical evidence that the majority of the disease gene pairs assume values in the range of 0.5--0.6, much greater than those assumed by the majority of all the remaining human genes (around 0.4). This clearly indicates that the NSHL genes are more functionally related in terms of similarity than two generic human genes. In order to statistically support this result, we formulated the following test: the null hypothesis is that the pair-wise *SSM* distribution in the disease genes set is equal to the pair-wise *SSM* distribution in the All-human-genes set, while the alternative hypothesis is that the former is greater than the latter, i.e. the cdf (cumulative distribution function) of the former population is smaller than the cdf of the latter population. The test was performed using the bootstrap version of the Kolmogorov-Smirnov test (ks.boot), which allows ties and is included in the R package Matching [@pone.0012742-R1]. We found a *p-value* , confirming the hypothesis that the disease genes are indeed more similar according to than two generic human genes. This evidence shows the ability of our metric in capturing the functional relatedness of NSHL genes respect to the rest of all human genes, justifying therefore a gene prioritization strategy for association with NSHL based on the similarity of the candidate genes with respect to the disease gene set.

![Similarity population pyramid.\
Back-to-back histograms showing the asymmetry in frequencies of SSM values (in 0.1 bin interval between 0 and 1) among gene pairs, for disease genes (on the right) and the entire human gene set (on the left).](pone.0012742.g001){#pone-0012742-g001}

In order to validate the reliability of in ranking the candidate genes with respect to their probability to play a causative role in NSHL manifestation, we designed a specific cross-validation procedure that quantifies how much the ranking obtained with our metric differs from a random ordering of the candidate genes. Indeed, due to the specific context we are dealing with, i.e. the gene prioritization, we could not use the classical cross-validation procedure, we in fact added 15% of the disease genes randomly drawn for 10000 times from the disease gene set to the candidates, and counted each time the number of the diseases that fell in the top four windows of 100, 75, 50 and 8 genes. Here the candidate gene set was used exclusively to produce noise, as the positions of the candidates in the ranking were never evaluated during the cross-validation procedure. We in fact tested if the number of disease genes ranked in the top windows were significantly greater than expected when a random extraction of 100, 75, 50 and 8 genes was performed from the total (candidates plus 15% of disease genes) gene set. In [Figure 2](#pone-0012742-g002){ref-type="fig"} we report the distributions obtained from the cross-validation procedure (in blue) applied to the four top windows. In this figure we compare these distributions with the hypergeometric ones (in red), which mimic the random extraction of 100, 75, 50 and 8 genes from the 8748 genes (8740 candidate genes plus 8 disease genes). In all four cases the two distributions are clearly distinct (i.e. the overlapping regions are small). Moreover the means of the distributions for the cross-validation (blue triangles in the figure) result always greater than the means of the hypergeometric distributions (red triangles in the figure). This confirms that the ranking computed by our gene scoring system is significantly different from a random ordering. This is equivalent to assert that our scoring system is able to put at the top of the ranking those genes which are functionally more related to the NSHL genes and thus, more likely, potentially to cause the disease when mutated. This evidence is statistically supported as the *p-value* and the *power* of the test for each of the four windows (see [Methods](#s4){ref-type="sec"} section) resulted always smaller than 0.01 and greater than 0.99, respectively ([Table 2](#pone-0012742-t002){ref-type="table"}).

![Cross-validation and hypergeometric distributions in case of (a)100, (b)75, (c)50, (d)8 window widths.\
In red the hypergeometric distributions with their expectation values (red filled triangles); in blue the distributions, estimated by cross-validation, of disease genes in the top-ranked genes with their mean values (blue filled triangles).](pone.0012742.g002){#pone-0012742-g002}

10.1371/journal.pone.0012742.t002

###### Gene scoring system cross-validation.

![](pone.0012742.t002){#pone-0012742-t002-2}

  Window Width    Mean Value   P-value   Power
  -------------- ------------ --------- -------
  100               5.845                  1
  75                5.313                  1
  50                4.502                0.999
  8                 1.151                  1

Window width indicates the number of top-ranked genes considered in the cross-validation procedure; mean value is the number of disease genes for each window averaged on the 10000 cross-validations; *p-value* and *power* are computed as described in the text.

Analysis of the top-ranked candidate genes {#s2b}
------------------------------------------

The candidates ranked according to were then examined looking at their functions and expression sites. The twenty top-scored genes are reported in [Table 3](#pone-0012742-t003){ref-type="table"} together with a brief description of their functions. The number of 20 was arbitrarily chosen, mainly thinking about the intrinsic technical limitations of experimentally testing a great number of genes for disease association -- this is actually the reason why such prioritization studies are becoming routine.

10.1371/journal.pone.0012742.t003

###### Top-ranked candidate genes.

![](pone.0012742.t003){#pone-0012742-t003-3}

  Gene symbol               Gene description                                                            Ear expression                                                             Gene Functions for NSHL
  ------------- ----------------------------------------- ------ --------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  WDR1                     WD repeat domain 1              0.55                        H. sapiens (ear)[a](#nt104){ref-type="table-fn"}                                              regulation of hair
                                                                                    M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                          cell actin dynamics[f](#nt110){ref-type="table-fn"}
  ALMS1                    Alström syndrome 1              0.53                     M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                             normal function of cilia [@pone.0012742-Li2]
  CD151                      CD151 molecule                0.52                possible human inner ear component [@pone.0012742-KaramaticCrew1]                    inner ear ECM assembly [@pone.0012742-KaramaticCrew1]
                           (Raph blood group)                                       M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                    
  CLRN1                         clarin 1                   0.52                     M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                         inner ear development[f](#nt110){ref-type="table-fn"}
                                                                                   widely expressed in human[b](#nt105){ref-type="table-fn"}                        F actin organization[f](#nt110){ref-type="table-fn"}
                                                                                                                                                                     protein trafficking[f](#nt110){ref-type="table-fn"}
  ABHD5              abhydrolase domain containing 5       0.52                     M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                            TG accumulation[f](#nt110){ref-type="table-fn"}
                                                                                                                                                                      lipid homeostasis[f](#nt110){ref-type="table-fn"}
  USH1G                     Usher syndrome 1G              0.52   H. sapiens (inner ear)[b](#nt105){ref-type="table-fn"} ^,^ [c](#nt106){ref-type="table-fn"}   cohesion of hair cell bundles[f](#nt110){ref-type="table-fn"}
                                                                                                                                                                                  (ankyrin and pdz domains)
  ATP6V0A4                ATPase H transporting            0.51          H. sapiens (cochlea)[b](#nt105){ref-type="table-fn"} [@pone.0012742-Stover1]                cochlear pH homeostasis [@pone.0012742-Wangemann1]
                         lysosomal V0 subunit a4                                                                                                               
  PRCD              progressive rod-cone degeneration      0.50                                             no data                                                                      no evidence
  KCNQ1              potassium voltage-gated channel       0.50                     M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                               K cycling[f](#nt110){ref-type="table-fn"}
                       KQT-like subfamily member 1                                                                                                             
  NUMB                  numb homolog (Drosophila)          0.50                        H. sapiens (ear)[a](#nt104){ref-type="table-fn"}                                            cell fate determination
                                                                                    M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                          during development[f](#nt110){ref-type="table-fn"}
  ZAR1                       zygote arrest 1               0.50             M. musculus (cochlea, stria vascularis)[g](#nt109){ref-type="table-fn"}                                      no evidence
  PTPLA             protein tyrosine phosphatase-like      0.50                   H. sapiens (fetal cochlea)[d](#nt107){ref-type="table-fn"}                         signal transduction[f](#nt110){ref-type="table-fn"}
                 (proline instead of catalytic arginine)                                                                                                       
                                member A                                                                                                                       
  FLII              flightless I homolog (Drosophila)      0.50                   H. sapiens (fetal cochlea)[d](#nt107){ref-type="table-fn"}                                          actin remodeling
  PTPN11              protein tyrosine phosphatase         0.49                        H. sapiens (ear)[a](#nt104){ref-type="table-fn"}                              signal transduction[f](#nt110){ref-type="table-fn"}
                          non-receptor type 11                                      M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                    
  TBL1X             transducin (beta)-like 1X-linked       0.49                   H. sapiens (fetal cochlea)[d](#nt107){ref-type="table-fn"}                         signal transduction[f](#nt110){ref-type="table-fn"}
                                                                                                    M. musculus (inner ear)                                        vescicular trafficking[f](#nt110){ref-type="table-fn"}
                                                                                                                                                                    cytoskeleton assembly[f](#nt110){ref-type="table-fn"}
  KCNE1L                       KCNE1-like                  0.49                     M. musculus (inner ear)[a](#nt104){ref-type="table-fn"}                               K cycling[f](#nt110){ref-type="table-fn"}
  TIMM8A           translocase of inner mitochondrial      0.49                                             no data                                                  signal transduction[f](#nt110){ref-type="table-fn"}
                      membrane 8 homolog A (yeast)                                                                                                                    protein transport[f](#nt110){ref-type="table-fn"}
  ROM1                    retinal outer segment            0.49                   H. sapiens (fetal cochlea)[d](#nt107){ref-type="table-fn"}                            cell adhesion[f](#nt110){ref-type="table-fn"}
                           membrane protein 1                                                                                                                  
  CC2D2A                   coiled-coil and C2              0.49                                             no data                                                      Ca binding[f](#nt110){ref-type="table-fn"}
                          domain containing 2A                                                                                                                         cilia formation[f](#nt110){ref-type="table-fn"}
  BARHL1                  BarH-like homeobox 1             0.48                     M.musculus (inner ear)[e](#nt108){ref-type="table-fn"}                                         external sensory organ
                                                                                                                                                                         fate determination [@pone.0012742-Bulfone1]

Gene expression information are taken from

NCBI Unigene [@pone.0012742-NCBI1],

UniProtKB [@pone.0012742-UniProtKB1],

HPRD database [@pone.0012742-HPRD1],

Morton Cochlear EST database [@pone.0012742-The1], NCBI GEO [@pone.0012742-NCBI2],

the table of gene expression in the developing ear from the Institute of Hearing Research [@pone.0012742-IHR1],

Bgee dataBase for Gene Expression Evolution [@pone.0012742-Bgee1] and literature. Gene function information have been inferred from

NCBI Gene [@pone.0012742-Maglott1] and literature.

Half of them are reported in literature to be expressed in human inner ear or cochlea, despite the very limited availability of gene expression data for these tissues due to the technical difficulties of obtaining undamaged hair-cell samples for gene expression experiments. For the remaining genes, six are reported to be expressed in other organisms\' inner ear or cochlea, mainly mouse or chicken, while four have no gene expression data for these tissues. Taken altogether, these are important indications supporting the goodness of the ranking we produced in respect to the NSHL, especially if we think that the initial candidate gene list was not *a priori* filtered by any criterium except that of being all annotated genes located in the susceptibility loci.

Moreover, looking at their functions, we found that most of the top-ranked genes play roles compatible with a possible involvement in NSHL phenotype. Among the most relevant, we identified a) processes of remodeling and organization of actin (WDR1, CLRN1, FLII), an essential component of the hair-cell bundle; b) formation and maintenance of cilia (ALMS1, USH1G, CC2D2A), the sensory organelles devoted to receive the mechanical stimulus; c) cycling and pH homeostasis in cochlear fluids (ATP6V0A4, KCNQ1, KCNE1L), essentials for the generation and maintenance of the endocochlear potential; d) signal transduction (PTPLA, PTPN11, TBL1X, TIMM8A). They are all important molecular mechanisms underlying the hearing process, which involve the hair cell capability to transduce the mechanical stimulus into electrical signal, as well as the endolymph production and maintenance.

Stronger evidences come from some of the top-ranked genes which are already linked to different syndromic forms of deafness: USH1G for instance is known to cause Usher syndrome type 1G [@pone.0012742-Weil1], associated with sensorineural hearing impairment; for this gene a possible role in the development and maintenance of the stereocilia bundles is reported by Weil et al. [@pone.0012742-Weil1]: it might in fact function as an anchoring/scaffolding protein in hair cells and could be involved in the functional network formed by USH1C, CDH23 and MYO7A that is required for cohesion of the growing hair bundle, making its role in the hearing impairment process quite easily explainable. Similarly, KCNE1L has been associated by Piccini et al. [@pone.0012742-Piccini1] to AMME syndrome (Alport syndrome - mental retardation - midface hypoplasia - elliptocytosis) whose symptoms include, among others, hearing loss, and analogous situations are reported also for TIMM8A, involved in Mohr-Tranebjaerg syndrome [@pone.0012742-Jin1] and Jensen syndrome [@pone.0012742-Tranebjaerg1], and ALMS1, involved in Alström syndrome [@pone.0012742-Collin1]. It is noteworthy that the association of some top-ranked genes to syndromic deafness forms does not exclude them from being good NSHL candidates, as clearly demonstrated by USH1C involved both in Usher syndrome type 1C [@pone.0012742-Verpy1], and NSHL [@pone.0012742-Ouyang1], [@pone.0012742-Ahmed1], depending on which mutations it undergoes.

Finally, we produced a graphical bidimensional representation of the 20 top-ranked genes together with the disease genes using Proxscal SPSS, which performs multidimensional scaling of similarity data to find a least squares representation of the objects in a low-dimensional space ([Figure 3](#pone-0012742-g003){ref-type="fig"}). The proximity of the two gene sets was in this way highlighted; this allowed identifying different groups of NSHL disease genes (red balls in the figure) -- namely myosins, connexins, cadherins, ion channels and so forth -- and mapping the best candidates within these groups. The inclusion of the top-scored candidate genes did not enlarge the area occupied by the disease genes and their membership to the relative subgroups was mantained in the graphical representation.

![Multidimensional scaling of similarity data to represent the disease and the 20 top-scored candidate genes in a bidimensional space.](pone.0012742.g003){#pone-0012742-g003}

Overall, on the basis of these considerations, the majority of them seem to be excellent candidates for subsequent studies on NSHL patients and controls.

Functional characterization of candidate and disease genes using GO {#s2c}
-------------------------------------------------------------------

In order to further investigate the obtained ranking and in order to have a more general picture of the molecular functions, biological processes and cellular components more associated to NSHL, as suggested by both the best candidates and disease genes, we designed and implemented two specific statistical tests that allowed to identify the GO terms more representative of NSHL, exploiting the score estimated by our gene scoring system. For the disease genes, we quantified and tested the enrichment of gene-sets defined by functional categories provided by Gene Ontology annotations in disease gene list. In this case the score was used to define the non-disease gene class (see [Methods](#s4){ref-type="sec"} section). For the candidates, we analyzed all GO terms in their annotations, and evaluated the enrichment of the gene set annotated with each of them, by using the score obtained from our ranking to quantify their association with NSHL (see Materials and [Methods](#s4){ref-type="sec"} section). In this case the score allowed us, starting from the GO terms associated to all the candidate genes, to identify those GO terms significantly associated with the best candidates, without making any *a priori* decision on which candidates should be considered as the "best" candidates.

This survey had the purpose to examine the ranking on a larger scale -- extending the ranking examination to the whole candidate gene set -- to possibly suggest non-obvious pathways to further look into when studying NSHL, hence it was devised as a way to look at the results from a different point of view (i.e. moving from a view of NSHL in terms of genes responsible of the disease to a view of NSHL in terms of biological processes, molecular functions and cellular components distinctive of the disease).

We considered as significantly descriptive of the best candidate and disease genes, those GO terms with a *p-value* and we ordered them according to their score, function of their *p-value* and specificity in the corpus of the GO annotations.

As for the candidate genes, the enriched terms, divided into biological processes, molecular functions and cellular components ([Table 4](#pone-0012742-t004){ref-type="table"}), include expected concepts such as "auditory receptor cell stereocilium organization" (GO:0060088), "large conductance calcium-activated potassium channel activity" (GO:0060072), "sensory perception of sound" (GO:0007605), "auditory receptor cell stereocilium organization" (GO:0060088), consistent with hearing physiology, as well as less obvious functions or processes such as "regulation of circadian sleep/wake cycle, REM and non-REM sleep" (GO:0042320, GO:0045188), "response to cocaine" (GO:0042220), or "mu-type opioid receptor binding" (GO:0031852), that need further (experimental) investigations. This on the one hand supports again the goodness of the ranking, confirming that the top-scored genes are actually promising candidates for association with NSHL, on the other hand fulfils our initial requirement to suggest new prospective insights in NSHL.

10.1371/journal.pone.0012742.t004

###### Enriched biological processes, cellular components and molecular functions for candidate genes.
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  GO term       Score   P-value                              Definition                                   Ontology
  ------------ ------- --------- ------------------------------------------------------------------ --------------------
  GO:0060082    17.0     0.002                            eye blink reflex                           biological process
  GO:0014010    16.3     0.005                       Schwann cell proliferation                      biological process
  GO:0034465    16.3     0.002                      response to carbon monoxide                      biological process
  GO:0060231    16.2     0.010                  mesenchymal to epithelial transition                 biological process
  GO:0021771    16.1     0.001                 lateral geniculate nucleus development                biological process
  GO:0032344    16.0     0.002              regulation of aldosterone metabolic process              biological process
  GO:0045759    16.0     0.001                negative regulation of action potential                biological process
  GO:0045794    15.9     0.002                   negative regulation of cell volume                  biological process
  GO:0021562    15.7     0.001                  vestibulocochlear nerve development                  biological process
  GO:0050975    15.6     0.005                      sensory perception of touch                      biological process
  GO:0051451    15.6     0.004                           myoblast migration                          biological process
  GO:0031630    15.5     0.005     regulation of synaptic vesicle fusion to presynaptic membrane     biological process
  GO:0048790    15.5     0.005            maintenance of presynaptic active zone structure           biological process
  GO:0046007    15.2     0.005         negative regulation of activated T cell proliferation         biological process
  GO:0046541    15.0     0.005                            saliva secretion                           biological process
  GO:0048676    14.9     0.005                 retinal bipolar neuron differentiation                biological process
  GO:0045188    14.9     0.001        regulation of circadian sleep/wake cycle, non-REM sleep        biological process
  GO:0050916    14.8     0.010                   sensory perception of sweet taste                   biological process
  GO:0035022    14.8     0.009         positive regulation of Rac protein signal transduction        biological process
  GO:0042524    14.9     0.005    negative regulation of tyrosine phosphorylation of Stat5 protein   biological process
  GO:0060083    14.7     0.002           smooth muscle contraction involved in micturition           biological process
  GO:0042320    14.7     0.001          regulation of circadian sleep/wake cycle, REM sleep          biological process
  GO:0051496    14.6     0.005             positive regulation of stress fiber formation             biological process
  GO:0030007    14.5     0.002                   cellular potassium ion homeostasis                  biological process
  GO:0001661    14.5     0.001                       conditioned taste aversion                      biological process
  GO:0051602    14.4     0.005                    response to electrical stimulus                    biological process
  GO:0032287    14.4     0.004          myelin maintenance in the peripheral nervous system          biological process
  GO:0050957    14.2     0.001                           equilibrioception                           biological process
  GO:0045475    14.1     0.002                            locomotor rhythm                           biological process
  GO:0001895    14.1     0.005                           retina homeostasis                          biological process
  GO:0060087    14.0     0.003                  relaxation of vascular smooth muscle                 biological process
  GO:0048484    14.0     0.007                   enteric nervous system development                  biological process
  GO:0022408    14.0     0.005               negative regulation of cell-cell adhesion               biological process
  GO:0060088    13.9     0.004            auditory receptor cell stereocilium organization           biological process
  GO:0021952    13.8     0.005         central nervous system projection neuron axonogenesis         biological process
  GO:0033081    13.8     0.004           regulation of T cell differentiation in the thymus          biological process
  GO:0051963    13.0     0.001                      regulation of synaptogenesis                     biological process
  GO:0042220    12.9     0.001                          response to cocaine                          biological process
  GO:0002262    12.9     0.004                        myeloid cell homeostasis                       biological process
  GO:0007019    12.7     0.005                      microtubule depolymerization                     biological process
  GO:0060113    12.5     0.001                inner ear receptor cell differentiation                biological process
  GO:0046620    12.4     0.004                       regulation of organ growth                      biological process
  GO:0007605    11.7     0.004                      sensory perception of sound                      biological process
  GO:0045039    11.5     0.005            protein import into mitochondrial inner membrane           biological process
  GO:0031667     9.9     0.004                      response to nutrient levels                      biological process
  GO:0019725     7.2     0.004                          cellular homeostasis                         biological process
  GO:0017071    15.9     0.005    intracellular cyclic nucleotide activated cation channel complex   cellular component
  GO:0032588    15.7     0.005                      trans-Golgi network membrane                     cellular component
  GO:0032839    14.1     0.004                           dendrite cytoplasm                          cellular component
  GO:0032154    13.9     0.005                            cleavage furrow                            cellular component
  GO:0016011    13.1     0.009                          dystroglycan complex                         cellular component
  GO:0042719    11.6     0.005     mitochondrial intermembrane space protein transporter complex     cellular component
  GO:0030660    10.3     0.005                   Golgi-associated vesicle membrane                   cellular component
  GO:0031852    17.0     0.005                    mu-type opioid receptor binding                    molecular function
  GO:0043533    16.3     0.008               inositol 1.3.4.5 tetrakisphosphate binding              molecular function
  GO:0060072    15.7     0.002     large conductance calcium-activated potassium channel activity    molecular function
  GO:0015266    14.4     0.004                        protein channel activity                       molecular function
  GO:0030346    14.2     0.004                     protein phosphatase 2B binding                    molecular function
  GO:0000822    13.8     0.008                   inositol hexakisphosphate binding                   molecular function

Candidate gene enriched (*p-value* ) GO terms, sorted according to their score in each ontology. scores take into account the specificity of the terms as described in the text.

As for the disease genes, as expected, the enriched terms are all consistent with the hearing physiology ([Table 5](#pone-0012742-t005){ref-type="table"}). To give some examples, among the most relevant enriched biological processes we found "actin filament-based movement" (GO:0030048), "inner ear morphogenesis" (GO:0042472), "regulation of cell shape" (GO:0008360) and a group involving sensory perception (GO:0007605, GO:0007601, GO:0050957). Likewise, among the enriched cellular components, are "stereocilium" (GO:0032420), "myosin complex" (GO:0016459), "cell junction" (GO:0030054), and among the molecular functions, "actin binding" (GO:0003779), "actin filament binding" (GO:0051015), and so forth.

10.1371/journal.pone.0012742.t005

###### Enriched biological processes, cellular components and molecular functions for disease genes.
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  GO term       Score   P-value                       Definition                             Ontology
  ------------ ------- --------- ----------------------------------------------------- --------------------
  GO:0007605    150.4                         sensory perception of sound               biological process
  GO:0007601    22.7                               visual perception                    biological process
  GO:0050957    22.7    0.0001                     equilibrioception                    biological process
  GO:0030048    21.2    0.0001               actin filament-based movement              biological process
  GO:0045494    19.5     0.001              photoreceptor cell maintenance              biological process
  GO:0050896    18.1                             response to stimulus                   biological process
  GO:0042472    17.8     0.001                  inner ear morphogenesis                 biological process
  GO:0008360    14.2     0.001                 regulation of cell shape                 biological process
  GO:0007155    14.0     0.001                       cell adhesion                      biological process
  GO:0006355    12.0    0.0005    regulation of cellular transcription, DNA-dependent   biological process
  GO:0006350    10.2     0.001                  cellular transcription                  biological process
  GO:0006810     7.8     0.009                         transport                        biological process
  GO:0005886    45.5                                plasma membrane                     cellular component
  GO:0016021    39.6                             integral to membrane                   cellular component
  GO:0005737    36.5                                   cytoplasm                        cellular component
  GO:0032420    24.7                                 stereocilium                       cellular component
  GO:0016459    23.0                                myosin complex                      cellular component
  GO:0005856    22.9                                 cytoskeleton                       cellular component
  GO:0030054    22.2                                 cell junction                      cellular component
  GO:0031941    21.9    0.0001                     filamentous actin                    cellular component
  GO:0005634    20.1                                    nucleus                         cellular component
  GO:0016324    19.8    0.0001                  apical plasma membrane                  cellular component
  GO:0001726    18.4     0.001                          ruffle                          cellular component
  GO:0005922    18.1     0.001                     connexon complex                     cellular component
  GO:0005829    16.9                                    cytosol                         cellular component
  GO:0005783    16.1    0.0001                   endoplasmic reticulum                  cellular component
  GO:0045202    15.2     0.001                          synapse                         cellular component
  GO:0016020    15.8                                   membrane                         cellular component
  GO:0042995    15.1    0.0001                      cell projection                     cellular component
  GO:0005789    14.4     0.001              endoplasmic reticulum membrane              cellular component
  GO:0003779    29.4                                 actin binding                      molecular function
  GO:0005516    28.5                              calmodulin binding                    molecular function
  GO:0051015    20.1    0.0001                  actin filament binding                  molecular function
  GO:0043531    19.8     0.001                        ADP binding                       molecular function
  GO:0003774    18.6                                motor activity                      molecular function
  GO:0005515    16.6                                protein binding                     molecular function
  GO:0004749    16.2     0.001         ribose phosphate diphosphokinase activity        molecular function
  GO:0042803    14.2     0.004               protein dimerization activity              molecular function
  GO:0005524    12.7    0.0001                        ATP binding                       molecular function
  GO:0043565    12.5     0.001               sequence-specific DNA binding              molecular function
  GO:0000166    11.9    0.0001                    nucleotide binding                    molecular function
  GO:0003700    11.6     0.001               transcription factor activity              molecular function

Disease gene enriched (*p-value* ) GO terms, sorted according to their score in each ontology. scores take into account the specificity of the terms as described in the text.

Interestingly, among all the enriched terms -- for both candidate and disease genes -- there is a very small amount of overlapping. Only two biological processes are in fact shared between the two gene lists, "sensory perception of sound" (GO:0007605) and "equilibrioception" (GO:0050957), which are neverthless extremely specific terms -- a very small number of gene products are annotated with these terms -- both deeply linked to the inner ear function. Looking at the GO graph, however, many of the non-shared terms are interconnected with each other on a larger scale, sharing a common parent at different levels of specificity. This is due to the structure of our algorithm that favours the closeness in the graph of the terms in estimating the similarity between genes. It is noteworthy that with this approach we can think of NSHL from a different perspective, exploring portions of the graph that otherwise would have never been explored.

In [Figure 4](#pone-0012742-g004){ref-type="fig"} we reported an elucidative example of this issue: by mapping some enriched disease and candidate biological processes to the GO graph, we observed that the addition of "inner ear receptor cell differentiation" (GO:0060113) to the list of NSHL possible biological processes clearly enlarges the NSHL subgraph covering a new branch of the "inner ear development" (GO:0048839) different from the "inner ear morphogenesis" (GO:0042472), while the addition of "auditory receptor cell stereocilium organization" (GO:0060088) narrows and specializes the concept "inner ear morphogenesis" to one of its components.

![GO subgraph of some disease and candidate gene enriched GO terms.\
Red circles indicate terms enriched for the disease genes, green circles indicate terms enriched for the candidate genes. Dark blue arrows indicate *is a* relations, light blue arrows indicate *part of* relations between the terms.](pone.0012742.g004){#pone-0012742-g004}

These findings, as a whole, on the one hand support again the goodness of the ranking, on the other hand they suggest that also some pathways apparently unrelated with NSHL, might deserve future attention by NSHL researchers.

Discussion {#s3}
==========

In the perspective of discovering new genes potentially involved in NSHL, we built a gene scoring system integrating Gene Ontology (GO), NCBI Gene and Map Viewer databases, which scores the candidate genes for NSHL by comparing them with the 51 NSHL disease genes already known, relying on the assumption that functionally related genes might contribute to the same (disease) phenotype.

We defined a set of candidate genes for NSHL as all the genes contained in the susceptibility loci known so far, and we prioritized them for the association with the disease, without making any *a priori* selection except that of being annotated with at least one GO term.

We first of all tested whether our metric, , was able to capture the above assumption, verifying that the disease genes are indeed more similar, according to the metric, than two generic human genes. We also demonstrated that our metric is able to pool the disease genes respect to the other human genes, implying that the former are indeed more closely functionally related than the latter: these results therefore justify a prioritization strategy based on the similarity of the candidate genes respect to the disease gene set.

Afterwards, we wanted to investigate to what extent our metric is reliable in ranking candidate genes for their potential role in NSHL manifestation. To this purpose we designed a cross-validation procedure and we obtained excellent results also considering the more disadvantageous condition of ranking eight disease genes in the first 8 positions of a list of more than 8700 genes.

Given these preliminary validations, we are extremely confident that the ranking we produced with respect to NSHL is worthy of attention for future NSHL research plan. Indeed, the top-scored candidate genes play all roles compatible with a possible involvement in NSHL phenotype, representing therefore excellent candidates for subsequent studies on NSHL patients and controls.

However two main limitations of this kind of approach should also be taken into account when looking at these data, both concerning the usage of Gene Ontology annotations to build the gene profiles on which the semantic similarity is measured. One is linked to the current knowledge about the human genome and its content in terms of genes. Indeed, the only prerequisite for a gene to be prioritized by our gene scoring system for a given disease is that of being annotated with at least one GO term, but, as clearly evidenced in this study, we are still far from the complete annotation of the entire human genome, as we were forced to exclude almost half of the possible candidates since they completely lacked GO annotations. This limitation obviously biases the results towards the best studied genes; however it will be progressively overcome in the future, due to the daily updates in this field. The other limitation regards the nature of the associations between GO terms and gene products. All the associations in Gene Ontology fall in five general categories indicating the evidences that support the annotation of a gene to a specific term. Four of these categories comprise exclusively manually-curated associations supported by experimental, computational analysis, author statements or curatorial statements. Unfortunately the great majority of GO associations does not fall in any of these manually-curated categories, being inferred from electronic annotation (IEA), which may open a debate on how reliable and precise they are. At present, given the high percentage of IEA associations in GO, it is not conceivable to discard them and consider only those manually-curated. Other solutions must therefore be devised to address this issue. Future developments of our gene scoring system could for instance take into account this problem by down-weighting the IEA associations respect to those manually-curated. However the quantification of the difference in weight between the manual and electronic associations is not trivial and requires an accurate study of the algorithms behind the electronic associations. We reserve in future to enhance our algorithm in this direction.

Final and essential step to confirm the results presented in this study is however the experimental validation. To this end two main aspects should be taken into account: (i) the accurate study and selection among the top-ranked genes of the most intringuing candidates for NSHL; we think for instance that the first one (WDR1) represents a good starting point, due to both what is known about its functions and structure -- it is indeed involved in the organization of the actin, fundamental for the auditory process, and small enough to be quite easily sequenced in a large number of subjects; (ii) an equally accurate selection of the appropriate NSHL patients and controls to be screened for causative mutations; it is advisable for instance to screen these genes on a cohort of patients already excluded to carry mutations in GJB2, due to the high incidence of NSHL cases caused by mutations in this gene, and on a control set appropriately matched for their geographic origin, in order to take into account the geographic distribution of the human DNA sequence variation.

Methods {#s4}
=======

A total of 15727 genes (candidate genes) were prioritized for NSHL in this study. We chose as candidate genes all the genes contained in the NSHL susceptibility loci known so far ([Tables S1](#pone.0012742.s001){ref-type="supplementary-material"}, [S2](#pone.0012742.s002){ref-type="supplementary-material"}, [S3](#pone.0012742.s003){ref-type="supplementary-material"} respectively for NSHL autosomal dominant, autosomal recessive and X-linked, Y-linked and modifier loci), so that all evidences coming from previous linkage analysis studies were taken into account.

We drew the complete disease gene list starting from the Hereditary Hearing Loss Homepage [@pone.0012742-Hereditary1] and a team of experts (geneticists and molecular biologists) further analysed the literature to find additional advances in the field by performing multiple queries on PubMed. To the best of our knowledge, 51 genes belong to this category, as reported in [Table 1](#pone-0012742-t001){ref-type="table"}.

For each disease and candidate gene, we extracted all their GO annotations using the file gene2go downloaded on 29th May 2009 from NCBI Entrez Gene ftp site [@pone.0012742-Maglott1]. One out of fifty-one disease genes -- MIRN96 -- had no GO annotations, therefore it was not included in this study, consequently narrowing the disease gene list to fifty genes. Likewise, 6987 out of 15727 candidate genes had no GO annotations, therefore the candidate gene list was consequently narrowed to 8740 genes.

Semantic similarity between two genes {#s4a}
-------------------------------------

As a node-based approach, our metric computes the similarity between two genes by comparing the GO terms describing them, their ancestors, and their descendants in the GO network. It is based on the *Information Content* (*IC*), which gives a measure of how specific and informative a term is. The *IC* of a term is quantified as the negative log likelihoodwhere is the probability of occurrence of in a specific corpus, which is normally estimated by the frequency of annotation of the term and its children in the GO structure [@pone.0012742-Bodenreider1], [@pone.0012742-Tlili1].

The concept of *IC* was used by Lin to quantify the semantic similarity between two terms in a tree-structured ontology, measuring the information they share normalized respect to the information contained in their total descriptions. According to Lin\'s metric [@pone.0012742-Lin1] the similarity between two terms and is defined as:where is the most informative common ancestor of the terms and , i.e. the common ancestor with the smallest .

However, two aspects of this metric limit its application:

-   it applies only to trees, where a unique most informative common ancestor between two any given concepts exists;

-   it measures the distance between single terms rather than set of terms.

For the first drawback, it is well known that in the case of a direct acyclic graph (DAG), such as GO, two terms can share parents by multiple paths, as multiple parents for each concept are allowed. Therefore, we chose, as , the minimum subsumer between and along all their independent paths to the graph root [@pone.0012742-Lord1].

To address the second issue, we defined our Semantic Similarity Measure (*SSM*) by directly extending Lin\'s idea to quantify the similarity between two concepts to the comparison between two gene products, i.e. two sets of concepts, therefore measuring the *IC* of the common description of the two gene products, normalized respect to the *IC* of their global description.

Let be two gene products, annotated respectively with and GO terms, that are to be compared. The idea is that each term in is an independent view of the gene and has to be compared with its counterpart in the gene annotation, namely the term in with maximum *IC* for the common description respect to it. In formulas, for the term , its counterpart in is defined as:The *IC* for each GO term *c* is estimated using its probability of occurrence in the corpus of all gene annotations provided by ENGINE database [@pone.0012742-Tulipano1], [@pone.0012742-GENe1]: in details, the probability is calculated for every term by counting the number of gene products associated with the term or any of its children, divided by the number of total associations between the GO terms and gene products.

Considering as independent the single views of a gene offered by each of its terms, the semantic similarity of respect to is estimated by the sum of the shared common description *IC*s between each term in and its counterpart in normalized with the *IC* of their global description:

The similarity of the gene respect to () is obtained by inverting the roles of and in the above formula. Finally, we defined our Semantic Similarity Measure between and , , as the mean between the similarity of respect to and the similarity of respect to : generates normalized similarity values between 0 and 1: it\'s equal to 0 for genes annotated with terms that share only the root and equal to 1 for genes annotated with the same terms.

Validation of the for NSHL gene prioritization {#s4b}
----------------------------------------------

A cross-validation procedure was used to check the reliability of the ranking of candidate genes for their involvement in NSHL. A random set of 8 disease genes was added to the set of candidate genes for 10000 times. Each time the values for this enlarged set of candidates were computed against the remaining disease genes and the number of disease genes in the first top-ranked positions was counted. The corresponding distributions of these countings were then compared with the probabilities of counting disease genes when a random drawn of 100, 75, 50, 8 genes, respectively, was performed from a set of 8748 genes (8740 candidate genes plus 8 disease genes): in the case of random drawns, the countings are described by a hypergeometric distribution with successes for *d* draws without replacement.

More in details, we computed the *p-value* and the *power* of a statistical test on the hypothesis of equal distributions against the hypothesis of a greater number of disease genes in the first positions for the ranked ordering respect to the random ordering. The *p-value* measures the probability to obtain, by random extraction, a number of disease genes greater than the mean value of the number of disease genes found in the top-ranked positions on the 10000 cross-validations:The *p-value* is our estimate of the probability of rejecting when is true: whenever the *p-value* was less than the significance level , we maintained that the number of disease genes found in the top-ranked positions was statistically significantly greater than that found in random orderings.

The knowledge of the empirical distribution of estimated through the cross-validation procedure, allowed us to estimate the *power* of the test with level : indicating with the -quantile of the hypergeometric distribution, is computed as follows:where is the number of disease genes found in the first positions for the randomization. The larger is the percentage of values obtained in cross-validation that are greater than , the more effective is the gene prioritization system.

Functional characterization of candidate and disease genes for NSHL {#s4c}
-------------------------------------------------------------------

### Candidate genes {#s4c1}

The statistical test used to identify the most representative GO terms associated with the candidate genes was designed as follows: the null hypothesis is that candidate genes annotated with a particular GO category have an average score equal to the average score expected for a random list of candidate genes with the same size, whereas the alternative hypothesis is that the GO category list has a higher average score and, therefore, is supposed to be more associated with the disease than a random candidate gene list. After selecting all the GO terms associated with all the candidate genes, we computed a *p-value* which scores each GO term according to the following strategy: the higher is the number of its associated candidates which obtained in our ranking a high value, the more the GO term is considered enriched in the candidate gene list. This implies that, choosing a significance threshold of 0.01, the GO terms with *p-value* can be considered significantly descriptive of the best candidate genes and consequently significantly associated with the disease. This provides directions for the NSHL researchers about the functions to be more deeply investigated in future laboratory experiments.

The *p-value* for the i-th GO term is computed as follows:where is the average of the scores resulting for candidate genes annotated with , is the number of candidate genes annotated with the category, is the empirical cumulative distribution for the scores, averaged on lists of candidate genes of size . was computed by drawing 10000 random lists of candidate genes of size and averaging the respective gene scores.

### Disease genes {#s4c2}

After selecting all the GO terms used to annotate the disease genes, we computed for each GO term a Fisher\'s exact test *p-value* which scores the GO category (GO Term C) highly for enrichment if many more disease genes than expected belong to the category. The contingency table ([Table 6](#pone-0012742-t006){ref-type="table"}) is built by counting the disease and non-disease genes associated and not associated with the GO category.

10.1371/journal.pone.0012742.t006

###### Contingency table.

![](pone.0012742.t006){#pone-0012742-t006-6}

  GO Term C                     Disease   Not Disease
  ---------------------------- --------- -------------
  Genes annotated with C                 
  Genes not annotated with C             

C represents the generic GO term in the disease gene GO annotations.

The definition of the non-disease class is not trivial, as it is not possible to know in advance which candidate genes will be discovered as responsible for NSHL in the future -- i.e. it is not possible to discriminate disease and non-disease genes among the candidates. To address this issue we decided to use the distribution of *SSM* scores in the class of candidate genes to define the non-disease class. We considered as non-disease genes the candidate genes with a score less than the 95th percentile of the distribution of candidate gene scores.

The GO terms with a Fisher\'s test *p-value* smaller than 0.01 are considered significantly over-represented in the list of the disease genes. These provide indications about the main functions and biological processes involved in the hearing mechanisms, taking into account the scores computed for our candidate gene list against the NSHL genes at present known.

### score {#s4c3}

For both candidate and disease gene lists their over-represented GO terms are weighted taking into account their specificity in the corpus of the GO annotations as follows:where *IC* is estimated using the probability of occurrence of the GO terms in the corpus of all gene annotations provided by ENGINE database [@pone.0012742-Tulipano1], [@pone.0012742-GENe1].
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